DUBLIN, Feb. 14, 2017 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will
report its 2016 fourth quarter and full year financial results on
Tuesday, February 28, 2017, after the
close of the financial markets. Company management will host
a live audio webcast immediately following the announcement at
4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter and full
year 2016 financial results and provide a business and financial
update and guidance for 2017 financial results.
Interested parties may access the live audio webcast via the
Investors section of the Jazz Pharmaceuticals website at
www.jazzpharmaceuticals.com. Please connect to the website
prior to the start of the conference call to ensure adequate time
for any software downloads that may be necessary to listen to the
webcast. A replay of the webcast will be archived on the
website for one week.
Audio webcast/conference call:
U.S. Dial-In
Number: +1 855 353 7924
International Dial-In Number: +1 503 343 6056
Passcode: 58716969
A replay of the conference call will be available through
March 7, 2017 and accessible through
one of the following telephone numbers, using the passcode
below:
Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number: +1 404 537 3406
Passcode: 58716969
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is an international biopharmaceutical company
focused on improving patients' lives by identifying, developing and
commercializing meaningful products that address unmet medical
needs. The company has a diverse portfolio of products and product
candidates, with a focus in the areas of sleep and
hematology/oncology. In these areas, Jazz Pharmaceuticals markets
Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase
Erwinia chrysanthemi) and Defitelio® (defibrotide sodium) in
the U.S. and markets Erwinase® and Defitelio® (defibrotide) in
countries outside the U.S. For more information, please visit
www.jazzpharmaceuticals.com.
Logo -
http://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg